(Q36946307)

17 August 2017

1 reference

title

Intensive diabetes therapy and body weight: focus on insulin detemir (English)

1 reference

17 August 2017

1 reference

Michael A Bush

1

1 reference

17 August 2017

publication date

1 August 2007

1 reference

Endocrinology and Metabolism Clinics of North America

17 August 2017

published in

1 reference

17 August 2017

volume

36 Suppl 1

1 reference

17 August 2017

page(s)

33-44

1 reference

Weight gain associated with intensive therapy in the diabetes control and complications trial. The DCCT Research Group

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

When oral agents fail: practical barriers to starting insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Weight gain associated with improved glycemic control in population-based sample of subjects with type I diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Weight changes following the initiation of new anti-hyperglycaemic therapies.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Combination therapies with insulin in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Improved glycemic control without weight gain using triple therapy in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Eating habits, body weight, and insulin misuse. A longitudinal study of teenagers and young adults with type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

At last, a weight neutral insulin?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Weight gain is associated with improved glycaemic control but with adverse changes in plasma lipids and blood pressure isn Type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Weight gain during insulin therapy in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Effects of insulin on body composition in patients with insulin-dependent and non-insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Improved glycemic control reduces the impact of weight gain on cardiovascular risk factors in type 1 diabetes. The Epidemiology of Diabetes Complications Study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Cardiovascular disease and its risk factors in IDDM in Europe. EURODIAB IDDM Complications Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Managing obesity and glycemic control in insulin-using patients: clinical relevance and practice recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Effect of BMI, insulin dose and number of injections on glycaemic control in insulin-using diabetic patients. Studygroup Diabetes Rijnmond (SDR)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Weight gain and insulin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Long term safety and efficacy of intraperitoneal insulin infusion by means of implantable pumps.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Glucose and free fatty acid turnover in normal subjects and in diabetic patients before and after insulin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Insulin detemir, does a new century bring a better basal insulin?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICT

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Dysregulation of insulin receptor substrate 2 in beta cells and brain causes obesity and diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Insulin signaling in the central nervous system: a critical role in metabolic homeostasis and disease from C. elegans to humans

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Increase in plasma leptin and Lep mRNA concentrations by food intake is dependent on insulin.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Intranasal insulin improves memory in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Tissue selectivity of insulin detemir action in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Comparison of Bedtime NPH or Preprandial Regular Insulin Combined With Glibenclamide in Secondary Sulfonylurea Failure

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Repaglinide versus glyburide: a one-year comparison trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

Effects of chronic intrahypothalamic infusion of insulin on food intake and diurnal meal patterning in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2980006-5

7 January 2021

10.1016/S0889-8529(07)80006-5

Identifiers

DOI

1 reference

17 August 2017

1 reference